百洋医药 reported revenue of ¥3.56B for the period ended 2026-06-30, -5.1% year on year. Net income was ¥0.28B, a 7.9% net margin on a 39.8% gross margin. The largest revenue line is 品牌产品销售推广业务 at 76% of the total. Free cash flow for the period was ¥-0.03B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥3.56B | -5.1% |
| Gross profit | ¥1.42B | — |
| Operating income | ¥0.34B | — |
| Net income | ¥0.28B | +32.4% |
| Gross margin | 39.8% | Net margin 7.9% |
| Revenue Q/Q | -0.5% | — |
| Segment | Revenue | Share |
|---|---|---|
| 品牌产品销售推广业务 | ¥2.72B | 76.5% |
| 医药批发配送业务 | ¥0.60B | 16.7% |
| 医药及健康产品零售业务 | ¥0.22B | 6.3% |
| 其他(补充) | ¥0.02B | 0.5% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥2.14B | 60.2% |
| R&D | ¥0.04B | 1.2% |
| SG&A | ¥0.95B | 26.7% |
| Tax & other | ¥0.06B | 1.7% |
| Item | Amount |
|---|---|
| Total assets | ¥7.98B |
| Total liabilities | ¥5.25B |
| Shareholders' equity | ¥2.73B |
| Equity / assets | 34.2% |
| Operating cash flow | ¥0.02B |
| Capital expenditure | ¥0.04B |
| Free cash flow | ¥-0.03B |
| Cash conversion (OCF / net income) | 14% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
雷尔伟 ・ 漱玉平民 ・ 申菱环境 ・ 宁波色母 ・ 密封科技 ・ 英诺激光 ・ 海泰科 ・ 奕帆传动 ・ 霍普股份 ・ 读客文化 ・ 浩通科技 ・ 华蓝集团
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies